ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck

July 11, 2016

  • Tweet
  • Email
Print-Friendly Version

A new immunotherapy doubles overall survival and improves quality of life with fewer side effects in previously treated metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), according to a large, randomized international trial.

You Might Also Like

  • Younger Patients with Oral Tongue Squamous Cell Carcinoma Have Better Survival Rates
  • High-Resolution Microendoscopy Shows Promise for Intraoperative Head and Neck Squamous Cell Carcinoma Margin Detection
  • Race Prognostic Factor for Overall Survival for Laryngeal Squamous Cell Carcinoma
  • Metastatic Cervical Squamous Cell Carcinoma from Occult Head and Neck Primary: A ‘Conservative’ Approach

The findings are from the international CheckMate-141 clinical trial, and were presented in June at the American Society of Clinical Oncology annual meeting.

“These exciting results indicate that there is a new standard of care option for a population of head and neck cancer patients with no other treatment options,” said Robert Ferris, MD, PhD, chief of the division of head and neck surgery and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, and the trial’s international co-chair.

The new drug, nivolumab, an immunotherapeutic, currently is approved to treat some types of cancers, including melanoma and lung cancer.

The phase III study enrolled 361 patients with recurrent or metastatic SCCHN who had not responded to platinum-based chemotherapy. Patients were randomized to receive either nivolumab or a single type of standard chemotherapy until tumor progression was observed. The median overall survival (OS) with nivolumab was 7.5 months compared with 5.1 months with investigator’s choice (HR, 0.70; 95% CI, 0.51-0.96; P = .0101). The objective response rate (ORR) was 13.3% with nivolumab and 5.8% for investigator’s choice. After 12 months, 36% of the nivolumab group was alive, compared with 17% of the standard chemotherapy group.

Additionally, nivolumab appeared to be most successful in patients with tumors positive for human papillomavirus (HPV).

The trial was funded by the drug manufacturer, Bristol-Myers Squibb, which is now seeking FDA approval for the use of nivolumab in head and neck carcinoma.

Filed Under: Head and Neck, Online Exclusives, Practice Focus Tagged With: HNSCC, squamous cell carcinoma

You Might Also Like:

  • Younger Patients with Oral Tongue Squamous Cell Carcinoma Have Better Survival Rates
  • High-Resolution Microendoscopy Shows Promise for Intraoperative Head and Neck Squamous Cell Carcinoma Margin Detection
  • Race Prognostic Factor for Overall Survival for Laryngeal Squamous Cell Carcinoma
  • Metastatic Cervical Squamous Cell Carcinoma from Occult Head and Neck Primary: A ‘Conservative’ Approach

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Vertigo in the Elderly: What Does It Mean?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Why Virtual Grand Rounds May Be Here to Stay
    • Otolaryngologist Leverages His Love of Pinball into Second Business
    • These New Imaging Advances May Help to Protect Parathyroids
    • Is the Training and Cost of a Fellowship Worth It? Here’s What Otolaryngologists Say
    • Which Otologic Procedures Poses the Greatest Risk of Aerosol Generation?

Polls

Have you used 3D-printed materials in your otolaryngology practice?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.